I am seeking a detailed discussion regarding the formulation and clinical efficacy of Life Space Probiotics. Specifically, I am interested in understanding the underlying mechanisms proposed by the manufacturer, including the strain selection rationale and the targeted modulation of the gut microbiome. What current peer‐reviewed evidence exists to support the specific claims made regarding immunomodulatory and gastrointestinal barrier functions? Additionally, have there been any comparative clinical trials evaluating Life Space Probiotics against other multi-strain products in terms of clinical outcomes for conditions such as irritable bowel syndrome or inflammatory bowel disease? Clarification on these points will be helpful for those assessing the potential integration of such products into complementary treatment regimens.